Please see below all current lung cancer clinical trials of the Central Coast Cancer Centre.
Name: DREAM3R
A phase 3 Randomised trial DuRvalumab (MEDI4736) with chEmotherapy as first line treAtment in advanced pleural Mesothelioma.
Principal Investigator: Dr Matthew Chan
Study Coordinator: Michelle Dixon
Status: Recruiting
Condition: Lung Cancer- Mesothelioma
More information about DREAM3R
Name: PACIFIC 9
Phase III, double-blind, placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy.
Principal Investigator: Dr Matthew Chan
Study Coordinator: Michelle Dixon
Status: Recruiting
Condition: Non-Small Lung Cancer
More information about PACIFIC 9
Name: LAGOON
A Randomised, Multicentre, Open-label, Phase III Study of Lurbinectedin Single-Agent or Lurbinectedin in Combination with Irinotecan versus Investigator’s Choice (Topotecan or Irinotecan) In Relapsed Small Cell Lung Cancer (SCLC) patients. LAGOON.
Principal Investigator: Dr Matthew Wong
Study Coordinator: Michelle Dixon
Status: Recruiting
Condition: Small Cell Lung Cancer
More information about LAGOON
Name: HLX10-020-SCLC302
A randomised, double-blind, International Multicentre, Phase III Study to evaluate the Efficacy and safety of HLX10 in combination with Chemotherapy and Concurrent Radiotherapy in Patients with Limited-Stage Small Cell Lung Cancer.
Principal Investigator: Dr Matthew Chan
Study Coordinator: Cassandra Rubio
Status: Recruiting
Condition: Small Cell Lung Cancer
More information about HLX10-020-SCLC302
More information
For more information about medical oncology clinical trials please contact the Nurse Unit Manager on 02 4320 9890 or see:
Research and Clinical Trials